January 17, 2021
Business News

Echosens Announces Acceptance of Actuarial Study in American Journal of Managed Care: Positive Return on Investment of VCTE/CAP FibroScan Technology to Measure Liver Fat and Stiffness

WALTHAM, Mass.–()–Echosens, a high-technology company offering the FibroScan family of products, announces acceptance of its article for publication of the findings of an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) to evaluate from the payer’s perspective the cost effectiveness of deploying VCTE / CAP machines (FibroScan®) for detecting and monitoring fatty liver disease (FLD). Scheduled for publication in 2021 by the American Journal of Managed Care, the report, “Population-Based Return on Investment of Deploying Transient Elastography Screening and Monitoring Fatty Liver Disease,” concluded that early identification of patients with FLD through broad placement of VCTE/CAP…

Click here to view the original article.

Related Posts

You might also like ...

Mitsubishi Electric and Tokyo Tech Develop Blockchain Technology to Optimize P2P Energy Trading
AON Splash Image
As Major Offshore Windstorm Approaches, PG&E Prepares for Potential Widespread, Wind-Driven Outages Throughout Its Service Area and Potential for Targeted Public Safety Power Shutoffs in Small Portions of the Driest Locations
Mayo Clinic Laboratories and American Hospital Dubai Announce Strategic Partnership